ERBB2 and breast cancer: For example, the monoclonal antibody trastuzumab is the recommended treatment during the initial stages of HER2 + BC; it is either administered alone (monotherapy) or in combination with cytotoxic agents (taxane), followed by doxorubicin therapy [13,14].